German Charité & Multinational Pharma Bayer Conduct Clinical Trial Evaluating Niclosamide Targeting COVID-19

German Charité & Multinational Pharma Bayer Conduct Clinical Trial Evaluating Niclosamide Targeting COVID-19

One of the largest university hospitals in Europe, Charité also represents a leading research institution, laying claim to more than half of all German Nobel Prize winners in Physiology or Medicine, including Emil von Behring, Robert Koch, and Paul Ehrlich. Internationally renowned for excellence in teaching and training, their Charité Research Organization has teamed with German pharmaceutical company Bayer thanks to funds from the Berlin Institute of Health to run the NICCAM clinical trial. A Phase 2 study, the study investigators and support team investigate the safety and tolerability of the treatment combination of niclosamide and camostat, the latter a study drug also under investigation by the American National Institutes of Health (NIH). Also focusing on the collection of efficacy data.  Recently, Charité along with University of Bonn and the German Center for Infection Research (DZIF) jointly issued a press release highlighting this interesting clinical trial.

Basis of the Study

The result of early on drug repurposing research targeting SARS-CoV-2, the virus behind COVID-19, scientists from the German Center for Infection Research (DZIF) at Charité Universitätsmedi...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee